Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:CGON NASDAQ:LEGN NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$191.99+1.2%$189.57$118.03▼$208.16$11.83B0.39372,022 shs273,288 shsCGONCG Oncology$37.54+2.9%$29.26$14.80▼$40.47$2.86B0.871.18 million shs619,313 shsLEGNLegend Biotech$33.37+1.7%$36.61$27.34▼$51.77$6.16B0.281.11 million shs793,652 shsROIVRoivant Sciences$15.17+1.4%$12.55$8.73▼$16.05$10.36B1.159.49 million shs6.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%-2.88%-1.17%+11.23%+32.75%CGONCG Oncology0.00%+1.73%+39.97%+44.38%-0.87%LEGNLegend Biotech0.00%-1.88%-3.92%-5.97%-32.27%ROIVRoivant Sciences0.00%+0.86%+27.16%+34.61%+32.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$191.99+1.2%$189.57$118.03▼$208.16$11.83B0.39372,022 shs273,288 shsCGONCG Oncology$37.54+2.9%$29.26$14.80▼$40.47$2.86B0.871.18 million shs619,313 shsLEGNLegend Biotech$33.37+1.7%$36.61$27.34▼$51.77$6.16B0.281.11 million shs793,652 shsROIVRoivant Sciences$15.17+1.4%$12.55$8.73▼$16.05$10.36B1.159.49 million shs6.57 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%-2.88%-1.17%+11.23%+32.75%CGONCG Oncology0.00%+1.73%+39.97%+44.38%-0.87%LEGNLegend Biotech0.00%-1.88%-3.92%-5.97%-32.27%ROIVRoivant Sciences0.00%+0.86%+27.16%+34.61%+32.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$244.3627.28% UpsideCGONCG Oncology 2.92Moderate Buy$56.5550.63% UpsideLEGNLegend Biotech 2.91Moderate Buy$74.22122.42% UpsideROIVRoivant Sciences 3.00Buy$19.9431.43% UpsideCurrent Analyst Ratings BreakdownLatest CGON, ROIV, ASND, and LEGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/26/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$41.00 ➝ $47.009/18/2025ROIVRoivant SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/18/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/18/2025ROIVRoivant SciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.009/18/2025ROIVRoivant SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $20.009/18/2025ROIVRoivant SciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $16.509/18/2025ROIVRoivant SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $22.009/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$56.00 ➝ $79.009/15/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/8/2025CGONCG OncologyJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 9/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M30.06N/AN/A($1.88) per share-102.12CGONCG Oncology$1.14M2,510.90N/AN/A$9.63 per share3.90LEGNLegend Biotech$627.24M9.82N/AN/A$5.70 per share5.85ROIVRoivant Sciences$29.05M356.60N/AN/A$7.45 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A799.96N/A-54.94%N/A-24.31%11/13/2025 (Estimated)CGONCG Oncology-$88.04M-$1.77N/AN/AN/A-15,945.17%-19.37%-18.72%11/11/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest CGON, ROIV, ASND, and LEGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/8/2025Q2 2025CGONCG Oncology-$0.49-$0.54-$0.05-$0.54$0.11 millionN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69CGONCG OncologyN/A22.1522.15LEGNLegend Biotech0.304.714.57ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ACGONCG Oncology26.56%LEGNLegend Biotech70.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%CGONCG OncologyN/ALEGNLegend Biotech0.02%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.62 million36.97 millionOptionableCGONCG Oncology6176.25 millionN/AOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableCGON, LEGN, ASND, and ROIV HeadlinesRecent News About These CompaniesRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from AnalystsSeptember 27 at 6:16 AM | marketbeat.comRoivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeptember 25, 2025 | seekingalpha.comRoivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 416,182 Shares of StockSeptember 24, 2025 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 SharesSeptember 23, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 SharesSeptember 23, 2025 | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 683,818 Shares of StockSeptember 23, 2025 | marketbeat.comAre You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd.September 23, 2025 | zacks.comRoivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call TranscriptSeptember 23, 2025 | seekingalpha.comBrokers Issue Forecasts for ROIV Q1 EarningsSeptember 22, 2025 | marketbeat.comQ2 EPS Forecast for Roivant Sciences Increased by AnalystSeptember 22, 2025 | americanbankingnews.comLeerink Partnrs Issues Optimistic Forecast for ROIV EarningsSeptember 22, 2025 | marketbeat.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comHC Wainwright Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $20.00September 20, 2025 | americanbankingnews.comLeerink Partners Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comGuggenheim Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20, 2025 | americanbankingnews.comBank of America Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $16.50September 20, 2025 | americanbankingnews.comMatthew Gline Purchases 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $24.00September 19, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $20.00 Price Target at JPMorgan Chase & Co.September 19, 2025 | marketbeat.comGuggenheim Increases Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00September 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGON, LEGN, ASND, and ROIV Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$191.99 +2.25 (+1.19%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$191.84 -0.15 (-0.08%) As of 09/26/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.CG Oncology NASDAQ:CGON$37.54 +1.06 (+2.91%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$37.56 +0.02 (+0.04%) As of 09/26/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Legend Biotech NASDAQ:LEGN$33.37 +0.55 (+1.68%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$33.30 -0.07 (-0.21%) As of 09/26/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Roivant Sciences NASDAQ:ROIV$15.17 +0.21 (+1.40%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$15.10 -0.07 (-0.46%) As of 09/26/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
